Dyanavel Xr 5 is a drug owned by Tris Pharma Inc. It is protected by 4 US drug patents filed from 2021 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 24, 2038. Details of Dyanavel Xr 5's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11590081 | Extended release amphetamine tablets |
Sep, 2038
(13 years from now) | Active |
| US9675704 | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | Active |
| US8337890 | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | Active |
| US8747902 | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dyanavel Xr 5's patents.
Latest Legal Activities on Dyanavel Xr 5's Patents
Given below is the list of recent legal activities going on the following patents of Dyanavel Xr 5.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 May, 2024 | US8337890 |
| Recordation of Patent Grant Mailed Critical | 28 Feb, 2023 | US11590081 |
| Patent Issue Date Used in PTA Calculation Critical | 28 Feb, 2023 | US11590081 |
| Email Notification Critical | 11 Feb, 2023 | US11590081 |
| Issue Notification Mailed Critical | 08 Feb, 2023 | US11590081 |
| Application Is Considered Ready for Issue Critical | 02 Feb, 2023 | US11590081 |
| Dispatch to FDC | 02 Feb, 2023 | US11590081 |
| Issue Fee Payment Received Critical | 01 Feb, 2023 | US11590081 |
| Issue Fee Payment Verified Critical | 01 Feb, 2023 | US11590081 |
| Email Notification Critical | 02 Nov, 2022 | US11590081 |
US patents provide insights into the exclusivity only within the United States, but Dyanavel Xr 5 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Dyanavel Xr 5's family patents as well as insights into ongoing legal events on those patents.
Dyanavel Xr 5's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Dyanavel Xr 5's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 24, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Dyanavel Xr 5 Generics:
There are no approved generic versions for Dyanavel Xr 5 as of now.
Alternative Brands for Dyanavel Xr 5
Dyanavel Xr 5 which is used for treating Attention Deficit Hyperactivity Disorder., has several other brand drugs in the same treatment category and using the same active ingredient (Amphetamine; Amphetamine Aspartate/dextroamphetamine Sulfate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc |
| |||||||||
About Dyanavel Xr 5
Dyanavel Xr 5 is a drug owned by Tris Pharma Inc. It is used for treating Attention Deficit Hyperactivity Disorder. Dyanavel Xr 5 uses Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate as an active ingredient. Dyanavel Xr 5 was launched by Tris Pharma Inc in 2021.
Approval Date:
Dyanavel Xr 5 was approved by FDA for market use on 04 November, 2021.
Active Ingredient:
Dyanavel Xr 5 uses Amphetamine; Amphetamine Aspartate/dextroamphetamine Sulfate as the active ingredient. Check out other Drugs and Companies using Amphetamine; Amphetamine Aspartate/dextroamphetamine Sulfate ingredient
Treatment:
Dyanavel Xr 5 is used for treating Attention Deficit Hyperactivity Disorder.
Dosage:
Dyanavel Xr 5 is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 4MG;EQ 1MG BASE | TABLET, EXTENDED RELEASE | Prescription | ORAL |